Works matching IS 10538569 AND DT 2021 AND VI 30 AND IP 1
Results: 14
A joint industry‐sponsored data monitoring committee model for observational, retrospective drug safety studies in the real‐world setting.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 9, doi. 10.1002/pds.5172
- By:
- Publication type:
- Article
Building an active medical product safety surveillance system in Taiwan: Adaptation of the U.S. Sentinel System common data model structure to the National Health Insurance Research Database in Taiwan.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 97, doi. 10.1002/pds.5168
- By:
- Publication type:
- Article
Medications used disproportionately during pregnancy: Priorities for research on the risks and benefits of medications when used during pregnancy.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 53, doi. 10.1002/pds.5131
- By:
- Publication type:
- Article
Real world data to identify target population for new CAR‐T therapies.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 78, doi. 10.1002/pds.5165
- By:
- Publication type:
- Article
Impact of a nationwide prospective drug utilization review program to improve prescribing safety of potentially inappropriate medications in older adults: An interrupted time series with segmented regression analysis.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 17, doi. 10.1002/pds.5140
- By:
- Publication type:
- Article
Patterns of anticonvulsant use and adverse drug events in older adults.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 28, doi. 10.1002/pds.5139
- By:
- Publication type:
- Article
Characteristics associated with time‐to‐treatment initiation for chronic Hepatitis C with new direct acting antivirals.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 86, doi. 10.1002/pds.5138
- By:
- Publication type:
- Article
Impact of a drug safety communication on the severity of benzonatate exposures reported to poison centers.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 45, doi. 10.1002/pds.5136
- By:
- Publication type:
- Article
Direct healthcare costs of chronic kidney disease management in Italy: What cost‐savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis‐stimulating agents?
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 65, doi. 10.1002/pds.5152
- By:
- Publication type:
- Article
Trends in HbA<sub>1c</sub> thresholds for initiation of hypoglycemic agents: Impact of changed recommendations for older and frail patients.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 37, doi. 10.1002/pds.5129
- By:
- Publication type:
- Article
Proton pump inhibitors and chronic kidney disease: Reevaluating the evidence from a randomized controlled trial.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 4, doi. 10.1002/pds.5101
- By:
- Publication type:
- Article
Leveraging neuropathological data in pharmacoepidemiology: A promising approach for dementia prevention?
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 1, doi. 10.1002/pds.5068
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 102, doi. 10.1002/pds.5040
- Publication type:
- Article
Issue Information.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2021, v. 30, n. 1, p. 1, doi. 10.1002/pds.5304
- Publication type:
- Article